The authors of the study concluded that the GLP-1 receptor agonist lixisenatide had a three-point beneficial effect, when compared with placebo, in the change over a 12-month period from a baseline value of approximately 15 points on a 132-point scale measuring motor disability. The active arm improved 0.04 points in the lixisenatide group and worsened 3.04 points in the placebo group
The truth is more nuanced: GLP-1 medications can be part of a long-term care plan, but ongoing success depends on understanding how appetite, metabolism, and daily habits work together
Approximately 66 million adults in Europe currently live with diabetes, representing a substantial patient population for GLP-1 therapies
Fully online testosterone replacement therapy (TRT) on the Al
The front or outer portion of the upper thigh provides the second most popular injection site
3 Beyond weight loss, the highest dose delivered meaningful reductions in cardiovascular risk factors: triglycerides fell by an average of 37.0%, non-HDL cholesterol by 16.5%, systolic blood pressure by 9.3 mmHg, waist circumference by 7.5 inches and high-sensitivity C-reactive protein by 51.2%